The trade mark protection is strategically important during AcuCort’s ongoing commercialisation phase. Glenmark Pharmaceuticals, with which AcuCort entered into a commercial partnership agreement in January 2026, will be responsible for the distribution, marketing and sales of Zeqmelit® in Ukraine.

“Securing trade mark protection for Zeqmelit® in Ukraine is an important addition to our international trade mark strategy. Strong intellectual property protection creates favourable conditions for our commercial partner Glenmark as the product is established on the Ukrainian market,” says Jonas Jönmark, CEO of AcuCort.

The protection resulting from the registration will remain in force in accordance with the dates applicable to the International Registration and will be renewed in connection with the renewal of the International Registration on 9 January 2033.

Zeqmelit® has been registered as a trade mark in all member states of the European Union, as well as in Norway, the United Kingdom, Switzerland, Australia, India, Israel, China, Japan, the United States, Canada and now Ukraine.

For further information: 
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.